Quentin Campbell‐Hewson

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

Ian Judson, James P. Morden, Lucy Kilburn et al. · The Lancet Oncology · 2019 · 95 citations · Full text

Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study

Nathalie Gaspar, Rajkumar Venkatramani, Stefanie Hecker‐Nolting et al. · The Lancet Oncology · 2021 · 90 citations

Phase 1/2, Malignant Disease, Medicine +8

Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆

Nathalie Gaspar, Quentin Campbell‐Hewson, Soledad Gallego et al. · ESMO Open · 2021 · 60 citations · Full text

A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson et al. · Clinical Cancer Research · 2014 · 55 citations

Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).

Nathalie Gaspar, Michela Casanova, Francisco Bautista et al. · Journal of Clinical Oncology · 2018 · 30 citations

Tumor Biology, Medicine, Metronomic Therapy +15